Dr Hyman speaks with ecancer at AACR 2017 to discuss results of the phase II SUMMIT trial of neratinib, which you can read more about here, or watch the press conference in which these results were presented. He describes the response of patients with...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2plZn4L
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Be a Responsible Dog Owner . Among companion animals, dogs are unmatched in their devotion, loyalty and friendship to humankind. Anyone who ...
-
is the premiere name in online OSHA Outreach training and safety courses. Our interactive courses include 10 hour and 30 hour OSHA Outreach,...
-
Masters Thesis Proposal Outline INTRODUCTION (1 PAGE) • What is the general topic area • Why this topic is relevant/important (how important...
-
Abstract We present a case of small coronary sinus defect detected after transcatheter device closure of a large secundum atrial septal de...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
An examination of the etiologic overlap between the genetic and environmental influences on insomnia and common psychopathology. Depre...
-
Publication date: Available online 5 April 2017 Source: European Annals of Otorhinolaryngology, Head and Neck Diseases Author(s): C.A. Ri...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGJfK4 via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου